tempol

Small moleculeexperimental

4-Hydroxy-TEMPO or TEMPOL, formally 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, is a heterocyclic compound. Like the related TEMPO, it is used as a catalyst and chemical oxidant by virtue of being a stable aminoxyl radical. Its major appeal over TEMPO is that it is less expensive, being produced from triacetone amine, which is itself made via the condensation of acetone and ammonia. This makes it economically viable on an industrial scale. — Wikipedia

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Sep 7, 2016 (NCT03680638)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)CC(O)CC(C)(C)N1[O]
Mol. weight
172.25 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • tempol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04729595Phase 2/Phase 3 (Phase 3)Sep 1, 2021Adamis Pharmaceuticals Corporation
NCT04874506Phase 2Jun 1, 2021Georgetown University, Matrix Biomed, Inc.
NCT04876755Phase 2May 30, 2021Matrix Biomed, Inc.
NCT03480971Phase 2Oct 31, 2018Matrix Biomed, Inc., University of Maryland
NCT03680404Phase 1Oct 1, 2018University of Texas, Arlington
NCT03680638Phase 1Sep 7, 2016University of Texas, Arlington
NCT04337099N/AMatrix Biomed, Inc.
NCT05491928N/AMatrix Biomed, Inc.
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Matrix Biomed, Inc.For profit5522018
University of Texas, ArlingtonAcademic/Hospital2212016
Adamis Pharmaceuticals CorporationFor profit1112021
Georgetown UniversityAcademic/Hospital1012021
University of MarylandAcademic/Hospital1012018
5 organizations
Page 1 / 1